Macrogenics Inc (MGNX)
3.24
+0.03
(+0.93%)
USD |
NASDAQ |
Nov 22, 16:00
3.25
+0.01
(+0.31%)
After-Hours: 20:00
Macrogenics Free Cash Flow: -61.71M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -61.71M |
| June 30, 2024 | -157.02M |
| March 31, 2024 | -113.88M |
| December 31, 2023 | -79.97M |
| September 30, 2023 | -22.38M |
| June 30, 2023 | 3.134M |
| March 31, 2023 | -44.66M |
| December 31, 2022 | -90.58M |
| September 30, 2022 | -175.19M |
| June 30, 2022 | -181.90M |
| March 31, 2022 | -179.48M |
| December 31, 2021 | -150.03M |
| September 30, 2021 | -103.44M |
| June 30, 2021 | -112.69M |
| March 31, 2021 | -102.07M |
| December 31, 2020 | -117.80M |
| September 30, 2020 | -148.00M |
| June 30, 2020 | -139.99M |
| March 31, 2020 | -152.28M |
| December 31, 2019 | -138.56M |
| September 30, 2019 | -127.21M |
| June 30, 2019 | -150.24M |
| Date | Value |
|---|---|
| March 31, 2019 | -164.05M |
| December 31, 2018 | -178.19M |
| September 30, 2018 | -49.16M |
| June 30, 2018 | -49.17M |
| March 31, 2018 | -23.99M |
| December 31, 2017 | -15.00M |
| September 30, 2017 | -145.48M |
| June 30, 2017 | -56.47M |
| March 31, 2017 | -57.14M |
| December 31, 2016 | -55.06M |
| September 30, 2016 | -52.60M |
| June 30, 2016 | -110.65M |
| March 31, 2016 | -100.20M |
| December 31, 2015 | -22.86M |
| September 30, 2015 | -17.74M |
| June 30, 2015 | -22.51M |
| March 31, 2015 | 0.826M |
| December 31, 2014 | -36.33M |
| September 30, 2014 | -16.62M |
| June 30, 2014 | -1.968M |
| March 31, 2014 | -7.420M |
| December 31, 2013 | -17.13M |
Free Cash Flow Range, Past 5 Years
-181.90M
Minimum
Jun 2022
3.134M
Maximum
Jun 2023
-113.43M
Average
-115.84M
Median
Free Cash Flow Benchmarks
| KORU Medical Systems Inc | -1.755M |
| Apellis Pharmaceuticals Inc | -205.58M |
| NovaBay Pharmaceuticals Inc | -4.812M |
| Palatin Technologies Inc | -32.57M |
| iBio Inc | -16.93M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 60.16M |
| Cash from Investing (Quarterly) | 35.60M |
| Cash from Financing (Quarterly) | -0.068M |
| Free Cash Flow Per Share (Quarterly) | 0.9476 |
| Free Cash Flow to Equity (Quarterly) | 59.57M |
| Free Cash Flow Yield | -30.49% |